Mid-titer human convalescent plasma administration results in suboptimal prophylaxis against SARS-CoV-2 infection in rhesus macaques

Frontiers in Immunology

Immunology

Jay Rappaport¹  Robert V. Blair¹  Skye Spencer²  Brandon J. Beddingfield²  Nicholas J. Maness³  Chad J. Roy³  HongMei Gao⁴  David Montefiori⁵  Pyone Pyone Aye⁶  Kasi Russell-Lodrigue⁶  Lara A. Doyle-Meyers⁶ 

[1] Comparative Pathology, Tulane National Primate Research Center, Covington, LA, United States;Divisions of Microbiology, Tulane National Primate Research Center, Covington, LA, United States;Divisions of Microbiology, Tulane National Primate Research Center, Covington, LA, United States;Department of Microbiology and Immunology, Tulane School of Medicine, New Orleans, LA, United States;Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, United States;Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, United States;Department of Surgery, Duke University Medical Center, Durham, NC, United States;Veterinary Medicine, Tulane National Primate Research Center, Covington, LA, United States;

关键词: SARS-CoV-2;    COVID-19;    rhesus macaque;    convalescent plasma;    prophylaxis;   

DOI  :  10.3389/fimmu.2023.1085883

 received in 2022-10-31, accepted in 2023-01-26,  发布年份 2023

来源: Frontiers

【 摘 要 】

IntroductionSARS-CoV-2 is a respiratory pathogen currently causing a worldwide pandemic, with resulting pathology of differing severity in humans, from mild illness to severe disease and death. The rhesus macaque model of COVID-19 was utilized to evaluate the added benefit of prophylactic administration of human post-SARS-CoV-2 infection convalescent plasma (CP) on disease progression and severity.MethodsA pharmacokinetic (PK) study using CP in rhesus monkeys preceded the challenge study and revealed the optimal time of tissue distribution for maximal effect. Thereafter, CP was administered prophylactically three days prior to mucosal SARS-CoV-2 viral challenge.ResultsResults show similar viral kinetics in mucosal sites over the course of infection independent of administration of CP or normal plasma, or historic controls with no plasma. No changes were noted upon necropsy via histopathology, although there were differences in levels of vRNA in tissues, with both normal and CP seemingly blunting viral loads.DiscussionResults indicate that prophylactic administration with mid-titer CP is not effective in reducing disease severity of SARS-CoV-2 infection in the rhesus COVID-19 disease model.

【 授权许可】

Unknown   
Copyright © 2023 Beddingfield, Maness, Spencer, Rappaport, Aye, Russell-Lodrigue, Doyle-Meyers, Blair, Gao, Montefiori and Roy